Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

Abstract Background Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and comparable safety and immunogenicity to reference etanercept (ETN) in patients with moderate-to-severe chronic plaque-type psoriasis. Methods EQUIRA was a phase III, double-blind study co...

Full description

Bibliographic Details
Main Authors: Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, Maya H. Buch, Eugeniusz J. Kucharz, Yannick Allanore, Arthur Kavanaugh, Philip Young, Goran Babic
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Arthritis Research & Therapy
Subjects:
Biosimilar
Etanercept
Rheumatoid arthritis
SDZ ETN
Switch
Tumor necrosis factor inhibitor
Online Access:http://link.springer.com/article/10.1186/s13075-019-1907-x

Internet

http://link.springer.com/article/10.1186/s13075-019-1907-x

Similar Items